Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

scientific article

Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/GCC.21975
P698PubMed publication ID22674490

P50authorTorsten HaferlachQ66370751
Tamara AlpermannQ66370761
Ulrike BacherQ66370775
Claudia HaferlachQ66370782
Susanne SchnittgerQ66370791
P2093author name stringWolfgang Kern
P2860cites workThe impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemiaQ27851416
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupQ27851459
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemiaQ27851642
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisQ34523534
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual diseaseQ34524219
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative GroupQ34692984
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARAQ35596919
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemiaQ35792858
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemiaQ35849643
Structural and numerical variation of FLT3/ITD in pediatric AML.Q36657987
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicinQ39821930
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptorQ39981715
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaQ40543180
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.Q45929224
The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patientsQ47320656
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.Q55035685
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2Q83310318
P433issue10
P304page(s)910-924
P577publication date2012-06-04
P1433published inGenes, Chromosomes and CancerQ5532697
P1476titleDiversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
P478volume51

Reverse relations

cites work (P2860)
Q28072539'Acute myeloid leukemia: a comprehensive review and 2016 update'
Q54325426Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3-ITD to detect patients with prognostically adverse AML.
Q92915669Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
Q34939070Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies
Q56968572Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
Q38675400FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Q38101284FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Q38200564FLT3 inhibitors in AML: are we there yet?
Q28289859FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Q39282600FLT3-ITD and its current role in acute myeloid leukaemia
Q38892684FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
Q52366350FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
Q93023707Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
Q42361918Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia
Q36823385Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo
Q60950398Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway
Q48161438Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
Q46576832Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.
Q26799606Molecular Genetic Markers in Acute Myeloid Leukemia
Q39116878Molecular landscape in acute myeloid leukemia: where do we stand in 2016
Q38664735Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Q38154339Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing
Q33798909Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
Q47965108Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Q38216649The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Q39045272The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.

Search more.